Search
Search titles only
By:
Search titles only
By:
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Forums
New posts
All threads
Latest threads
New posts
Trending threads
Trending
Search forums
What's new
New posts
New ads
New profile posts
Latest activity
Free Ads
Latest reviews
Search ads
Members
Current visitors
New profile posts
Search profile posts
Contact us
Latest ads
Ad icon
Sell your Land, House on idamata.lk for FREE
sajith.xp.pk
Updated:
Thursday at 9:03 AM
Handmade Character Soft Toys
anil1961
Updated:
Tuesday at 2:11 PM
Bodim.lk out now !
Manoj Suranga Bandara
Updated:
Sunday at 3:05 AM
Power Lifting Lever Belt
SkullVamp
Updated:
Jun 13, 2026
Ad icon
port.lk Domain for sale
Lankan-Tech
Updated:
Jun 13, 2026
Electronics
Vehicles
Property
Search
Reply to thread
Forums
General
ElaKiri Talk!
Chikungunya Vaccines
Get the App
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="imhotep" data-source="post: 30786105" data-attributes="member: 562115"><p>Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), an RNA virus belonging to the <em>Alphavirus</em> genus within the family <em>Togaviridae</em>. Primarily transmitted by bites from infected <em>Aedes</em> mosquitoes (<em>Aedes aegypti</em> and <em>Aedes albopictus</em>), the disease is characterized by the sudden onset of fever, joint pain (arthralgia), and rashes, with approximately 50% of detected acute cases developing chronic joint pain that may persist for several months. CHIKV-associated mortality is rare (~1 death per 1,000 cases)</p><p></p><p>The recently licensed IXCHIQ vaccine (VLA1553, Valneva Austria GmbH), has received both the FDA & EMA approval for individuals 18 years of age and older who are at increased risk of exposure to CHIKV. The EMA approval is for 18 - 64 only. They recommend that Ixchiq must not be given to people aged 65 years and older or people who are immunodeficient or immunosuppressed (have a weakened immune system) due to a disease or treatment.</p><p></p><p>The FDA and CDC are recommending (7 May 2025) a pause in the use of Ixchiq (Chikungunya Vaccine, Live) in individuals 60 years of age and older while the Agencies investigate postmarketing reports of serious adverse events, including neurologic and cardiac events, in individuals who have received the vaccine.</p><p><strong>As of May 7, 2025, 17 serious adverse events, including two that resulted in death, have been reported in individuals 62 through 89 years of age who received Ixchiq during postmarketing use globally. </strong></p><p><strong>It's a live attenuated vaccine using the strain CHIKV LR2006-OPY1.</strong></p><p><strong></strong></p><p><strong>Also there's VIMKUNYA™ </strong>by Bavarian Nordic. It's a Recombinant vaccine, the first virus-like particle (VLP) single-dose chikungunya vaccine and the first chikungunya vaccine for individuals over the age of 12. It's EMA and FDA approved for over 12 year olds.</p></blockquote><p></p>
[QUOTE="imhotep, post: 30786105, member: 562115"] Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), an RNA virus belonging to the [I]Alphavirus[/I] genus within the family [I]Togaviridae[/I]. Primarily transmitted by bites from infected [I]Aedes[/I] mosquitoes ([I]Aedes aegypti[/I] and [I]Aedes albopictus[/I]), the disease is characterized by the sudden onset of fever, joint pain (arthralgia), and rashes, with approximately 50% of detected acute cases developing chronic joint pain that may persist for several months. CHIKV-associated mortality is rare (~1 death per 1,000 cases) The recently licensed IXCHIQ vaccine (VLA1553, Valneva Austria GmbH), has received both the FDA & EMA approval for individuals 18 years of age and older who are at increased risk of exposure to CHIKV. The EMA approval is for 18 - 64 only. They recommend that Ixchiq must not be given to people aged 65 years and older or people who are immunodeficient or immunosuppressed (have a weakened immune system) due to a disease or treatment. The FDA and CDC are recommending (7 May 2025) a pause in the use of Ixchiq (Chikungunya Vaccine, Live) in individuals 60 years of age and older while the Agencies investigate postmarketing reports of serious adverse events, including neurologic and cardiac events, in individuals who have received the vaccine. [B]As of May 7, 2025, 17 serious adverse events, including two that resulted in death, have been reported in individuals 62 through 89 years of age who received Ixchiq during postmarketing use globally. It's a live attenuated vaccine using the strain CHIKV LR2006-OPY1. Also there's VIMKUNYA™ [/B]by Bavarian Nordic. It's a Recombinant vaccine, the first virus-like particle (VLP) single-dose chikungunya vaccine and the first chikungunya vaccine for individuals over the age of 12. It's EMA and FDA approved for over 12 year olds. [/QUOTE]
Insert quotes…
Verification
Awruddata maasa keeyada?
Post reply
Top
Bottom